Xencor, Inc Increase (Decrease) in Accounts Receivable
Xencor, Inc (XNCR) reported Increase (Decrease) in Accounts Receivable of $22.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- Xencor, Inc increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $28.44M, a 224.28% increase year-over-year.
- Xencor, Inc increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$5.80M.
- Xencor, Inc increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $8.77M.
- Xencor, Inc increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was -$23.41M.
- Xencor, Inc increase (decrease) in accounts receivable for fiscal 2025 was -$28.73M, a 187.94% decline from fiscal 2024.
- Xencor, Inc increase (decrease) in accounts receivable for fiscal 2024 was $32.67M.
- Xencor, Inc increase (decrease) in accounts receivable for fiscal 2023 was -$19.83M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|
| 2026-06-30 | $28.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $22.64M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$5.80M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | -$28.73M 10-K · filed 2026-02-25 | ||
| 2025-06-30 | $8.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$14.64M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | -$23.41M 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $32.67M 10-K · filed 2026-02-25 | ||
| 2023-12-31 | -$19.83M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |